龙8娱乐

当前位置: 首页 > 药学版 > 药品研究 > 药物评价 > 正文
编号:176470
Hiv蛋白酶抑制剂研究进展
http://www.100md.com 2002年5月25日 新药网
     罗华军,蔡水洪5ti, http://www.100md.com

    (华东理工大学化工学院,上海,200237)5ti, http://www.100md.com

    【摘要】 HIV蛋白酶抑制剂是一类具有高度选择性的高效抗艾滋病药物。研究表明,HIV蛋白酶的作用是将gag和gag-pol基因表达产生的多聚蛋白裂解,变成各种有活性的病毒结构和酶,抑制该酶的活性会产生无感染能力的未成熟的子代病毒,从而阻止病毒进一步感染。本文介绍了已上市或正在临床研究的沙奎那韦、利托那韦、茚地那韦、奈非那韦、Am-prenavir、Lopinavir、BMS-232632等HIV蛋白酶抑制剂的作用机制、药理、疗效不良反应、剂量及用法。5ti, http://www.100md.com

    【关键词】 HIV蛋白酶抑制剂;沙奎那韦;利托那韦;茚地那韦;奈非那韦;Amprenavir;Lopinavir5ti, http://www.100md.com

    Progress of HIV protease inhibitors5ti, http://www.100md.com

    LUO Hua-jun,CAI Shui-hong5ti, http://www.100md.com

    (Department of Chemical Engineering,East China University of Science and Technology,Shanghai 200237)5ti, http://www.100md.com

    【Abstract】 HIV protease inhibitors are potent and highly selective anti-AIDS agents.The HIV protease enzyme is responsible for processing of the gag and gag-pol gene polyprotein products into functional viral enzymes and proteins.Inhibition of the protease leads to the formation of immature,noninfectious virions and results in repression of viral replication.In this paper,the mechanism of action,pharmacokinetic properties,therapeutic efficacy,side effects,dosage and administration of HIV protease inhibitors,including saquinavir,ritonavir,indinavir,nelfinavir,amprenavir,lopinavir,BMS-232632 etc. were reviewed.

    【Key words】 HIV protease inhibitors;saquinavir;ritonavir;indinavir;nelfinavir;amprenavir;lopinavirff0(g, 百拇医药

    【作者简介】ff0(g, 百拇医药

    罗华军(1974-),男,湖北三峡大学讲师,现为华东理工大学硕士研究生,主要从事手性药物的研究与开发,联系电话:(021)64252345,E-mail:luohuajun@21cn.com。ff0(g, 百拇医药

    【参考文献】ff0(g, 百拇医药

    [1] 张素敏,朱珠,李大魁.干扰素在治疗爱滋病相关综合征中的应用[J].中国新药杂志,1998,7(4):284-287.ff0(g, 百拇医药

    [2] 艾滋病在地球[N].南方周末,2000-11-30(4).ff0(g, 百拇医药

    [3] 曾毅,陈启民,耿运琪.人免疫缺陷病毒(HIV)[A].见:曾毅主编.艾滋病毒及其相关病毒[M].天津:南开大学出版社,1999.14-15.ff0(g, 百拇医药

    [4] 宋力崴,李伟章.HIV蛋白酶抑制剂与药物相互作用[J].国外医学药学分册,1999,26(6):337-341.ff0(g, 百拇医药

    [5] Noble S,Faulds D.Saquinavir:A review of its pharmacology and clinical potential in the management of HIV infection[J].Drugs,1996,52(1):93-112.ff0(g, 百拇医药

    [6] Drugs Future,1997,22(3):315-316.ff0(g, 百拇医药

    [7] Figgitt DP,Plosker GL.Saquinavir soft-gel capsule:A updated review of its use in the management of HIV infection[J].Drugs,2000,60(2):481-516.ff0(g, 百拇医药

    [8] Graul A,Castaner J.Ritonavir[J].Drugs Future,1996,21(7):700-705.

    [9] Drugs Future,1999,24(7):821.:c, 百拇医药

    [10] Mealy N,Castaner J.Indinavir sulfate[J].Drugs Future,1996,21(6):600-609.:c, 百拇医药

    [11] Polsker GL,Noble S.Indinavir:A review of its use in the management of HIV infection[J].Drugs,1999,58(6):1165-1203.:c, 百拇医药

    [12] Kaldor SW,Kalish VJ,Davies JF,et al.Viracept(Nelfinavir mesylate,AG1343):A potent orally bioavailable inhibitor of HIV-1 protease[J].J Med Chem,1997,40(24):3979-3981.:c, 百拇医药

    [13] Pai VB,Nahata MC.Nelfinavir mesylate:A protease inhibitor[J].Ann Pharmacother,1999,33(3):325-329.:c, 百拇医药

    [14] Drugs Future,1999,24(4):460.:c, 百拇医药

    [15] Anne BE,Polsker GL.Nelfinavir:A update on its use in HIV infection[J].Drugs,2000,59(3):581-620.:c, 百拇医药

    [16] Painter GR,Ching S,Reynolds D,et al.141W94[J].Drugs Future,1996,21(4):347-350.:c, 百拇医药

    [17] Drugs Future,1998,23(4):438.:c, 百拇医药

    [18] Drugs Future,1999,24(4):442-444.:c, 百拇医药

    [19] Hurst M,Faulds D.Lopinavir[J].Drugs,2000,60(6):1371-1379.:c, 百拇医药

    [20] Rabasseda X,Silvestre J,Castaner J.BMS-232632[J].Drugs Future,1999,24(4):375-380.:c, 百拇医药

    [21] Wroblewski T,Graul A,Castaner J.PNU-140690[J].Drugs Future,1998,23(2):146-151.:c, 百拇医药

    [22] Drugs Future,2001,26(2):206-207.:c, 百拇医药

    [23] Ireland CD,Castaner J.KNI-272[J].Drugs Future,1996,21(10):1022-1027.:c, 百拇医药

    [24] Drugs Future,1999,24(10):1138-1139.
龙8娱乐qy8千亿国际欢迎您qy8千亿国际亚虎娱乐老虎机
亚虎娱乐老虎机龙8娱乐老虎机梦之城娱乐梦之城娱乐
亚虎娱乐老虎机qy8千亿国际欢迎您qy8千亿国际龙8娱乐官网
龙8娱乐龙8娱乐城开户送8 88龙8娱乐老虎机亚虎娱乐老虎机
亚虎娱乐老虎机龙8娱乐老虎机梦之城娱乐梦之城娱乐